AGRX Agile Therapeutics Inc.

1.34
+0.05  (+4%)
Previous Close 1.29
Open 1.29
Price To Book 2.39
Market Cap 58,615,849
Shares 43,743,171
Volume 336,734
Short Ratio
Av. Daily Volume 208,845

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRLs issued 2013 and 2017. New PDUFA date November 16, 2019. Advisory Committee Meeting October 30, 2019.
Twirla
Contraceptive patch

Latest News

  1. Agile Therapeutics Announces FDA Advisory Committee Meeting for its Investigational Transdermal Low-Dose Contraceptive Patch, Twirla® (AG200-15)
  2. Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®
  3. Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Low-Dose Contraceptive Patch, Twirla®
  4. Agile Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference
  5. Agile Therapeutics to Present Combined Safety Data from Three Phase 3 Studies at the 2019 ACOG Annual Meeting
  6. Agile Therapeutics: 1Q Earnings Snapshot
  7. Agile Therapeutics Reports First Quarter 2019 Financial Results
  8. Agile Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference in London, UK
  9. Agile Therapeutics to Present In Vivo Adhesion Data from Two Phase 1 Studies at the 2nd Annual Formulation & Drug Delivery USA Congress
  10. AGRX: Numerous Catalysts in 2019…
  11. Agile Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
  12. Agile Therapeutics to Present at Upcoming Investor Conferences
  13. Agile Therapeutics Announces $7.8 Million Private Placement
  14. AGRX: Positive Results for Twirla® Adhesion Study; NDA Resubmission in 2Q19
  15. Agile Therapeutics, Inc. Announces that Twirla® Meets Primary Endpoint in Comparative Wear Study and Demonstrates Non-Inferior Adhesion to Xulane®
  16. Agile Therapeutics to Present at the 2019 BIO CEO and Investor Conference
  17. AGRX: Twirla® Adhesion Study Underway; NDA Resubmission in 2Q19…
  18. The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA
  19. Agile Therapeutics, Inc. Provides Regulatory Update and Reiterates Cash Guidance